Natera, Inc. (NTRA) Reports Preliminary Q4 Revenue
Natera, Inc. (NASDAQ:NTRA) announced preliminary fourth-quarter 2025 revenue of $660 million, exceeding the average forecast of $577.62 million, as reported by TheFly on January 12, 2026.
Natera Inc. (NTRA)
Market is closed
Sector: Services-Medical Laboratories
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 3,914,366 | $896,742,107 | -8% | 4.23% |
| 2. | Coatue Management Philippe Laffont | 2,633,334 | $603,270,486 | +1447% | 1.51% |
| 3. | AQR Capital Management Cliff Asness | 2,599,299 | $595,473,319 | +9% | 0.31% |
| 4. | Castle Hook Partners Josh Donfeld And David Rogers | 2,167,869 | $496,637,110 | +25% | 2.06% |
| 5. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 1,179,939 | $270,312,226 | +112% | 0.16% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $29.56 | 19,011 | $562,054.51 | 420,000 | 2022-05-12 | Filing | |
| $28.81 | 159,783 | $4,603,348.23 | 400,989 | 2022-05-12 | Filing | |
| $28.09 | 41,026 | $1,152,358.80 | 241,026 | 2022-05-12 | Filing | |
| $33.49 | 40,695 | $1,362,798.23 | 1,291,584 | 2022-03-16 | Filing | |
| $32.59 | 85,903 | $2,799,982.51 | 1,250,889 | 2022-03-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $230.77 | 1,639 | $378,228.75 | 137,847 | 2026-02-03 | Filing | |
| $234.00 | 16 | $3,744.00 | 139,486 | 2026-02-02 | Filing | |
| $233.24 | 600 | $139,942.02 | 139,502 | 2026-02-02 | Filing | |
| $232.33 | 850 | $197,476.51 | 140,102 | 2026-02-02 | Filing | |
| $230.84 | 576 | $132,963.78 | 140,952 | 2026-02-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 12,854,334 | $2,944,799,683 | 0.18% | |
| 2. | 12,306,424 | $2,819,278,675 | 0.04% | |
| 3. | 10,859,441 | $2,487,789,346 | 0.04% | |
| 4. | 3,225,879 | $739,016,620 | 0.02% | |
| 5. | 2,608,644 | $596,077,841 | 0.04% |
News See All
Growth Stock Portfolio: 12 Stock Picks By Cathie Wood
After a severe 2022 decline, Cathie Wood's flagship innovation fund witnessed a dramatic comeback through 2025, climbing 87.1% in the year ending in September 2025 and tripling over three years, according...
Lack of Natera (NTRA) Exposure Weighs on Voya MidCap Opportunities Fund Performance
Voya Investment Management’s Voya MidCap Opportunities Fund released its Q4 2025 investor letter, titled “Seeking a More Favorable Risk/Return Trade-off”, outlining a quarter marked by solid market...
Natera (NTRA) Surged as Results Beat Expectations
Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Natera (NTRA) Announces Publication of Findings from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study
Natera, Inc. (NASDAQ:NTRA) is one of the High Growth Large Cap Stocks to Buy Right Now.
14 High Growth Large Cap Stocks to Buy Right Now
Chris Harvey, CIBC's equity and portfolio strategy head, recently appeared on CNBC television, highlighting that it anticipates the S&P 500 to reach 7,450.
J.P. Morgan Lifts Natera, Inc. (NTRA) Target on Signatera Momentum
TheFly reported on December 15 that J.P.
7 Most Promising Gene Editing Stocks According to Analysts
Gene editing has rapidly evolved into a transformative class of technologies that allow scientists to precisely insert, delete, or modify DNA within living cells.
TD Cowen Lifts Natera (NTRA) Target to $240, Reiterates Buy Rating
Natera, Inc. (NASDAQ:NTRA) is one of the best gene-editing stocks to buy according to hedge funds. On November 7, Daniel Brennan, an analyst at TD Cowen, reiterated a Buy rating on Natera, Inc.
9 Best Gene-Editing Stocks to Buy According to Hedge Funds
Genetic manipulation – or gene editing – is a concept that describes altering the genetic material (DNA) of an organism.
Hedge Fund Resource Center Billionaire Hedge Funds
